BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28623355)

  • 1. Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates.
    Novohradsky V; Zanellato I; Marzano C; Pracharova J; Kasparkova J; Gibson D; Gandin V; Osella D; Brabec V
    Sci Rep; 2017 Jun; 7(1):3751. PubMed ID: 28623355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells.
    Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
    Biochem Pharmacol; 2015 Jun; 95(3):133-44. PubMed ID: 25888926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Anticancer Pt
    Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
    Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action.
    Raveendran R; Braude JP; Wexselblatt E; Novohradsky V; Stuchlikova O; Brabec V; Gandin V; Gibson D
    Chem Sci; 2016 Mar; 7(3):2381-2391. PubMed ID: 29997781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.
    Cetraz M; Sen V; Schoch S; Streule K; Golubev V; Hartwig A; Köberle B
    Arch Toxicol; 2017 Feb; 91(2):785-797. PubMed ID: 27307157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands.
    Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
    J Inorg Biochem; 2014 Nov; 140():72-9. PubMed ID: 25063910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells.
    Alessio M; Zanellato I; Bonarrigo I; Gabano E; Ravera M; Osella D
    J Inorg Biochem; 2013 Dec; 129():52-7. PubMed ID: 24080480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cells.
    Almotairy ARZ; Montagner D; Morrison L; Devereux M; Howe O; Erxleben A
    J Inorg Biochem; 2020 Sep; 210():111125. PubMed ID: 32521289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
    Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
    Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
    Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
    Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt(NH3)2malSAHA-2H)].
    Brabec V; Griffith DM; Kisova A; Kostrhunova H; Zerzankova L; Marmion CJ; Kasparkova J
    Mol Pharm; 2012 Jul; 9(7):1990-9. PubMed ID: 22591133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position.
    Tolan D; Gandin V; Morrison L; El-Nahas A; Marzano C; Montagner D; Erxleben A
    Sci Rep; 2016 Jul; 6():29367. PubMed ID: 27404565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
    Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin.
    Zajac J; Kostrhunova H; Novohradsky V; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
    J Inorg Biochem; 2016 Mar; 156():89-97. PubMed ID: 26780576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers.
    Serebryanskaya TV; Yung T; Bogdanov AA; Shchebet A; Johnsen SA; Lyakhov AS; Ivashkevich LS; Ibrahimava ZA; Garbuzenco TS; Kolesnikova TS; Melnova NI; Gaponik PN; Ivashkevich OA
    J Inorg Biochem; 2013 Mar; 120():44-53. PubMed ID: 23305964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
    Siddik ZH; al-Baker S; Thai G; Khokhar AR
    Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
    Kido Y; Khokhar AR; al-Baker S; Siddik ZH
    Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects.
    Tabrizi L; Thompson K; Mnich K; Chintha C; Gorman AM; Morrison L; Luessing J; Lowndes NF; Dockery P; Samali A; Erxleben A
    Mol Pharm; 2020 Aug; 17(8):3009-3023. PubMed ID: 32628022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.